Vaccine Therapy in Preventing HPV in HIV-Positive Women in India

DISEASE CHARACTERISTICS: * HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by western blot before study entry * HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test * Meets 1 of the following criteria: * Nadir CD4 level of ≤ 350 cells/mm³ and receiving highly active antiretroviral therapy (HAART) for at least 6 months before study entry * Nadir CD4 level of \> 350 cells/mm³ and not receiving HAART at the time of study entry * No known history of high-grade CIN or cervical cancer PATIENT CHARACTERISTICS: * Karnofsky performance status 70-100% * ANC \> 750 cells/mm³ * Hemoglobin ≥ 9.0 g/dL * Platelet count ≥ 100,000/mm³ * Serum creatinine ≤ 3 times upper limit of normal (ULN) * AST and ALT ≤ 3.0 times ULN * Conjugated (direct) bilirubin ≤ 2.5 times ULN * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No active drug or alcohol use or dependence that would interfere with adherence to study requirements, in the opinion of the site Investigator * No serious illness requiring systemic treatment and/or hospitalization within the past 45 days * No allergy to yeast or any of the components of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine PRIOR CONCURRENT THERAPY: * See Disease Characteristics * More than 45 days since prior systemic antineoplastic or immunomodul…